微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 51.08% | 7.06% | 1.86% | 72/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 50.15% | 0.35% | 0.16% | 74/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 50.07% | -2.03% | 1.01% | 74/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 49.57% | -3.89% | 3.89% | 73/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 47.71% | -8.04% | -4.52% | 74/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 49.97% | -1.18% | -2.22% | 78/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 51.11% | 0.22% | -0.9% | 75/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 51.57% | 2.1% | -0.6% | 75/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 51.88% | 3.81% | 2.59% | 72/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 50.57% | -5.07% | -0.83% | 76/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 51% | -5.84% | 0.96% | 72/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 50.51% | -7.23% | 1.06% | 76/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 49.98% | -8.92% | -6.18% | 76/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 53.27% | -3.96% | -1.64% | 77/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 54.16% | -2.45% | -0.53% | 71/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 54.45% | -1.1% | -0.78% | 71/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 54.88% | -0.82% | -1.07% | 69/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 55.47% | -8.94% | -0.1% | 74/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 55.52% | -12.46% | 0.85% | 64/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 55.05% | -11.64% | -0.5% | 71/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 55.33% | -9.14% | -9.17% | 63/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 60.92% | -6.4% | -3.95% | 57/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 63.42% | -1.9% | 1.79% | 47/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 62.31% | -1.53% | 2.32% | 48/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 60.89% | 2.81% | -6.43% | 44/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 65.08% | 0.35% | 0.66% | 43/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 64.65% | 2.78% | 2.18% | 35/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 63.27% | 0.53% | 6.83% | 42/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 59.23% | -3.73% | -8.67% | 41/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 64.85% | 10.1% | 3.1% | 42/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 62.9% | 8.02% | -0.06% | 34/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 62.94% | 9.77% | 2.31% | 35/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 61.52% | 8.89% | 4.45% | 36/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 58.9% | 9.26% | 1.16% | 45/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 58.23% | 10.54% | 1.55% | 32/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 57.34% | 9.16% | 1.49% | 31/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 56.5% | 6.94% | 4.81% | 28/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 53.91% | 6.45% | 2.34% | 40/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 52.68% | 2.66% | 0.29% | 27/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 52.53% | 2.69% | -0.58% | 32/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 52.83% | 6.42% | 4.33% | 24/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |